Weekly Spotlight - 14.11.24

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

In the News

Diabetes and Kidney Disease Significantly Elevate Cardiovascular Risk

New research highlights that individuals with both type 2 diabetes and chronic kidney disease face a significantly increased risk of cardiovascular disease, potentially 28 years earlier than those without these conditions. Experts recommend a heart-healthy lifestyle, including diet and exercise, to mitigate these risks.

SC0062 Shows Promise for IgA Nephropathy Treatment

The 2-SUCCEED trial explored SC0062, a new treatment for IgA nephropathy, showing promising results. SC0062 significantly reduced proteinuria without causing peripheral oedema, offering hope for patients. The trial involved 131 participants and demonstrated a favourable safety profile, suggesting SC0062 as an effective option for managing this condition.

IgA Nephropathy: Understanding Progression and Key Risk Factors

IgA nephropathy (IgAN) is a condition where IgA deposits in the kidneys, leading to progressive damage. Key factors like persistent proteinuria, hypertension, and reduced GFR can accelerate progression to end-stage renal disease (ESRD). Understanding these factors is crucial for managing and potentially slowing IgAN progression.

SBP1's Role in IgA Nephropathy: A New Understanding

SBP1 plays a crucial role in IgA nephropathy by promoting mesangial cell proliferation and inflammation through mitochondrial respiration. Elevated SBP1 levels correlate with kidney damage, suggesting its potential as a therapeutic target. This discovery offers hope for better management of IgA nephropathy, improving patient outcomes.